February 2, 2024 11:08 AM EST
News Briefing

Hutchmed's li­cens­ing deal, worth up to $227M; Tyra's $200 PIPE

Jaimy Lee

Deputy Editor

Plus, news about An­bo­gen Ther­a­peu­tics and Ve­ra Ther­a­peu­tics:

Hutchmed inks deal of up to $227.5M: The com­pa­ny is li­cens­ing two drugs …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Trump blog: Judge ex­tends na­tion­wide block on NIH pay­ment cuts

RFK Jr. read­ies re­view of child­hood vac­cine sched­ule af­ter pledg­ing not to

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times